跨性别女性的前列腺癌:泌尿外科医生需要了解什么
本文通过非系统性综述现有文献、指南和实践标准,总结跨性别女性前列腺癌的10例病例报告、4篇专家意见、6项队列研究和4篇系统综述。未接受性别肯定激素治疗(GAHT)或性别肯定手术(GAS)的跨性别女性及性别不 conformity 个体,其前列腺癌风险与顺性别男性相同;接受GAHT或GAS后发病率低于年龄匹配的顺性别男性,但诊断和治疗更复杂。综述就筛查、诊断工具(如PSA和MRI)及治疗考虑提出建议。
要点
- 未接受GAHT或GAS的跨性别女性前列腺癌风险与顺性别男性相同,需讨论筛查、诊断和治疗选项。
- 接受GAHT或GAS的跨性别女性前列腺癌发病率低于年龄匹配的顺性别男性,但诊疗更复杂。
- 现有证据有限,需发展稳健的循证指南指导跨性别女性前列腺癌的诊断和管理。
核心结论
- 未接受GAHT或GAS的跨性别女性及性别不 conformity 个体的前列腺癌风险与顺性别男性相同。
- 接受GAHT或GAS的跨性别女性前列腺癌发病率低于年龄匹配的顺性别男性,但诊断和治疗更复杂。
研究设计与样本
- 非系统性综述,检索现有文献、当前指南和实践标准,纳入10例病例报告、4篇专家意见、6项队列研究和4篇系统综述。
主要发现
- 文献检索发现10例跨性别女性前列腺癌病例报告、4篇专家意见、6项队列研究和4篇系统综述。
- 未接受GAHT或GAS的跨性别女性及性别不 conformity 个体的前列腺癌风险与顺性别男性相同。
- 接受GAHT或GAS的跨性别女性前列腺癌发病率低于年龄匹配的顺性别男性。
关键数值与推荐
- 未接受GAHT或GAS的跨性别女性及性别不 conformity 个体,前列腺癌风险与顺性别男性相同,需讨论筛查、诊断和治疗选项并考虑未来性别肯定治疗意愿。
- 接受GAHT或GAS的跨性别女性,前列腺癌诊断和治疗更复杂,需考虑PSA和MRI等诊断工具的使用及治疗制定。
临床怎么用
- 对未接受GAHT或GAS的跨性别女性及性别不 conformity 个体,应就前列腺癌筛查、诊断和治疗选项进行讨论,并考虑未来性别肯定治疗意愿。
- 对接受GAHT或GAS的跨性别女性,诊断和治疗前列腺癌时需更细致地考虑PSA和MRI等工具的使用及治疗制定。
局限性
- 本文为非系统性综述,证据基础有限,需未来研究发展稳健的循证指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To review of the existing literature, current guidelines and standard of practice related to prostate cancer in transgender women, as the transgender population share many of the same healthcare needs as their cisgender counterparts, but may have additional specialist needs. MATERIALS AND METHODS: We performed a non-systematic review of the literature, current guidelines and standard of practice related to prostate cancer in transgender women. RESULTS: Our search revealed 10 case reports of prostate cancer in transgender women, four specialist opinion papers, six cohort studies, and four systematic reviews. The information in these publications were assimilated to produce a review of prostate cancer in transgender women. CONCLUSION: The risk of prostate cancer in transgender women who are not on gender-affirming hormone therapy (GAHT) or who have not had gender-affirming surgery (GAS) and gender non-conforming individuals (who may never commence GAHT or have GAS) is the same as that in the cis male population. In these patients, healthcare professionals need to be able to discuss screening, diagnostic and treatment options considering future wishes for gender-affirming treatment. Prostate cancer incidence in transgender women on GAHT or following GAS is lower than age-matched cis-male counterparts, but diagnosis and treatment is more nuanced. The present review discusses the existing literature about development and incidence of prostate cancer in this population, and makes recommendations about screening, the usefulness of diagnostic tools e.g. prostate-specific antigen and magnetic resonance imaging, and considerations when formulating treatment. Potential directions for future research are discussed, which will hopefully lead to development of robust evidence-based guidelines for the diagnosis and management of prostate cancer in transgender women.
引用
- Bertoncelli Tanaka M, Sahota K, Burn J, et al. Prostate cancer in transgender women: what does a urologist need to know? BJU Int. 2021. PMID: 34157213. doi:10.1111/bju.15521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。